{"id":11369,"date":"2026-05-27T01:01:00","date_gmt":"2026-05-26T23:01:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=a0445a5e1f46732cd6f7e9af410ddaf6"},"modified":"2026-05-27T01:01:00","modified_gmt":"2026-05-26T23:01:00","slug":"arcturus-therapeutics-to-present-at-2026-jefferies-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=11369","title":{"rendered":"Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference"},"content":{"rendered":"<p>SAN DIEGO--(BUSINESS WIRE)--<a href=\"https:\/\/twitter.com\/search?q=%24ARCT&src=ctag\" >$ARCT<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/65Roses?src=hash\" >#65Roses<\/a>--Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in New York:<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260526805188\/en\/837248\/5\/arcturus-logo-blueback.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260526805188\/en\/837248\/22\/arcturus-logo-blueback.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260526805188\/en\/837248\/5\/arcturus-logo-blueback.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260526805188\/en\/837248\/21\/arcturus-logo-blueback.jpg\" \/><\/a><p>\n<b>2026 Jefferies Global Healthcare Conference (Presentation)<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nThursday, June 4, 2026 (9:20 a.m. ET)<\/li>\n<\/ul><p>\nWebcast link can be found under Investor Relations\/Events section of Arcturus\u2019 <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54542009&amp;newsitemid=20260526805188&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3883e6f44e2a9b54b52311b4ccea165a\" rel=\"nofollow\" shape=\"rect\">website<\/a>.<\/p><p>\n<b>About Arcturus<\/b><\/p><p>\nFounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR\u00ae lipid-mediated delivery, (ii) STARR\u00ae mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE\u00ae, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus\u2019 pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus\u2019 versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ArcturusRx.com&amp;esheet=54542009&amp;newsitemid=20260526805188&amp;lan=en-US&amp;anchor=www.ArcturusRx.com&amp;index=2&amp;md5=2cf4b672dc686c7b0d9a44329faebca3\" rel=\"nofollow\" shape=\"rect\">www.ArcturusRx.com<\/a>. Please connect with us on <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Farcturusrx&amp;esheet=54542009&amp;newsitemid=20260526805188&amp;lan=en-US&amp;anchor=X&amp;index=3&amp;md5=6f1cfdd22e9d90cf8722842c56c4ae6f\" rel=\"nofollow\" shape=\"rect\">X<\/a> and <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Farcturus-therapeutics&amp;esheet=54542009&amp;newsitemid=20260526805188&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=6946a58d9b93ee4c3fb3bee23930726e\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a>.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Arcturus Therapeutics<\/b><br\/>Public Relations &amp; Investor Relations\n<br\/>Neda Safarzadeh\n<br\/>VP, Head of IR\/PR\/Marketing\n<br\/>(858) 900-2682\n<br\/><a  href=\"mailto:IR@ArcturusRx.com\" rel=\"nofollow\" shape=\"rect\">IR@ArcturusRx.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;$ARCT #65Roses&#8211;Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced &#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-11369","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11369"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11369\/revisions"}],"predecessor-version":[{"id":11370,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11369\/revisions\/11370"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}